A Phase 1 interventional study of Diclofenac sodium gel and Diclofenac diethylamine 1.16% gel in Healthy Volunteer, sponsored by Amzell. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-06.
Sponsored by Amzell · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of the present study is to investigate the systemic bioavailability of AMZ001, applied once daily on each knee compared to Diclofenac diethylammonium gel 1.16%, applied 4 times daily on each knee, after repeated dosing in healthy subjects for 7 days The safety and local tolerability of AMZ001, applied once daily, will be evaluated after repeated dosing in healthy subjects for 7 days
On their both knees, participants will apply once daily AMZ001 for 7 consecutive days. Participants will also apply Diclofenac Diethylammonium 1.16% Gel as per label information on each knee.
Intensive pharmacokinetic assessment (blood samplings) will be performed on the first day of application (Day 1) as well as on the last day of application (Day 7).
Each participant will receive each of the two treatments in a randomized manner. Between each treatment, participant will not receive any of tested therapies during at least 21 days before receiving the next therapy. (washout period)
Participants will stay on the clinical unit only during each period of treatment but not during washout period.
Amzell is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AMZ001 applied once daily for 7 consecutive days
Drug: Diclofenac sodium gel
Reference product applied four-times daily for 7 consecutive days
Drug: Diclofenac diethylamine 1.16% gel
topical administration
Topical administration
Area Under the Curve 0-24h
Area under the curve from time zero to 24 hours
Time frame: Day 7
Pharmacokinetic Parameter - Cmin
Minimum plasma drug concentration (Cmin)
Time frame: Day 7
Pharmacokinetic Parameter - Cavg
Average plasma concentration (Cavg)
Time frame: Day 7
Pharmacokinetic Parameter - Tmax
Time to reach maximum plasma concentration (Tmax)
Time frame: Day 7
Compare Exposure to Diclofenac
Area under the curve from time zero to 24 hours and maximum (peak) plasma drug concentration
Time frame: Day 1
Pharmacokinetic Parameter - Tmax
Time to reach maximum plasma concentration (Tmax)
Time frame: Day 1
Pharmacokinetic Parameter - Cavg
Average plasma concentration
Time frame: Day 1
Incidence of Application Site Reactions
Number of subjects having at least one event
Time frame: Day 1 to Day 7
| Milestone | AMZ001/Diclofenac Diethylamine 1.16% | Diclofenac Diethylamine 1.16%/AMZ001 |
|---|---|---|
| Started | 17 | 17 |
| Completed | 17 | 17 |
| Not completed | 0 | 0 |
| Milestone | AMZ001/Diclofenac Diethylamine 1.16% | Diclofenac Diethylamine 1.16%/AMZ001 |
|---|---|---|
| Started | 17 | 16 |
| Completed | 17 | 16 |
| Not completed | 0 | 0 |
Area under the curve from time zero to 24 hours
| h*ng/mL | AMZ001 | Diclofenac Diethylamine 1.16% |
|---|---|---|
| Area Under the Curve 0-24h | 281.60 ± 67.1 | 411.35 ± 57.2 |
Minimum plasma drug concentration (Cmin)
| ng/mL | AMZ001 | Diclofenac Diethylamine 1.16% |
|---|---|---|
| Pharmacokinetic Parameter - Cmin | 5.812 ± 73.1 | 10.22 ± 50.2 |
Average plasma concentration (Cavg)
| ng/mL | AMZ001 | Diclofenac Diethylamine 1.16% |
|---|---|---|
| Pharmacokinetic Parameter - Cavg | 11.733 ± 67.1 | 17.139 ± 57.2 |
Time to reach maximum plasma concentration (Tmax)
| h | AMZ001 | Diclofenac Diethylamine 1.16% |
|---|---|---|
| Pharmacokinetic Parameter - Tmax | 6 (0 to 20.017) | 17.9830 (0 to 24) |
Area under the curve from time zero to 24 hours and maximum (peak) plasma drug concentration
| h*ng/mL | AMZ001 | Diclofenac Diethylamine 1.16% |
|---|---|---|
| Compare Exposure to Diclofenac | 141.76 ± 101.6 | 86.76 ± 116.3 |
Time to reach maximum plasma concentration (Tmax)
| h | AMZ001 | Diclofenac Diethylamine 1.16% |
|---|---|---|
| Pharmacokinetic Parameter - Tmax | 9.9170 (4.000 to 23.833) | 23.8330 (8.000 to 23.883) |
Average plasma concentration
| ng/mL | AMZ001 | Diclofenac Diethylamine 1.16% |
|---|---|---|
| Pharmacokinetic Parameter - Cavg | 5.906 ± 101.6 | 3.615 ± 116.3 |
Number of subjects having at least one event
| Participants | AMZ001 | Diclofenac Diethylamine 1.16% |
|---|---|---|
| Incidence of Application Site Reactions | 0 | 1 |
Collected over From enrollment until end of treatment period 2. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AMZ001 | 0/33 (0%) | 0/33 (0%) | 5/33 (15.2%) |
| Diclofenac Diethylamine 1.16% | 0/34 (0%) | 0/34 (0%) | 8/34 (23.5%) |
| Event | AMZ001 | Diclofenac Diethylamine 1.16% |
|---|---|---|
| NasopharyngitisInfections and infestations | 2/33 | 3/34 |
| HeadacheNervous system disorders | 1/33 | 2/34 |
| Urinary tract infectionInfections and infestations | 1/33 | 0/34 |
| Abdominal pain upperGastrointestinal disorders | 1/33 | 0/34 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/33 | 0/34 |
| RhinitisInfections and infestations | 0/33 | 1/34 |
| Skin abrasionInjury, poisoning and procedural complications | 0/33 | 1/34 |
| DysuriaRenal and urinary disorders | 0/33 | 1/34 |
| ErythemaSkin and subcutaneous tissue disorders | 0/33 | 1/34 |
| Age, Continuous(years) | AMZ001/Diclofenac Diethylamine 1.16% | Diclofenac Diethylamine 1.16%/AMZ001 | Total |
|---|---|---|---|
| Mean | 47.2 ± 12.75 | 44.5 ± 9.94 | 45.8 ± 11.34 |
| Sex: Female, Male(Participants) | AMZ001/Diclofenac Diethylamine 1.16% | Diclofenac Diethylamine 1.16%/AMZ001 | Total |
|---|---|---|---|
| Female | 11 | 7 | 18 |
| Male | 6 | 10 | 16 |
| Race (NIH/OMB)(Participants) | AMZ001/Diclofenac Diethylamine 1.16% | Diclofenac Diethylamine 1.16%/AMZ001 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 17 | 15 | 32 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | AMZ001/Diclofenac Diethylamine 1.16% | Diclofenac Diethylamine 1.16%/AMZ001 | Total |
|---|---|---|---|
| Hispanic or Latino | 17 | 17 | 34 |
| Not Hispanic or Latino | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
Plan to share: Undecided
Ran from Nov 2024 to primary completion in Jun 2025, 6 months.
Results were first posted in Jan 2026, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diclofenac Sodium Gel
Amzell